3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Squamous Cell Carcinoma of Head and Neck
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Gallbladder Neoplasms
1
Endometrial Neoplasms
1
Carcinoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
5
Cisplatin
5
Oxaliplatin
2
pertuzumab
1
durvalumab
1
Trastuzumab
1
Standard of Care
1
Radiotherapy, Intensity-Modulated
1
Platinum
1
Paclitaxel
1
Magnetic Resonance Spectroscopy
1
Lymph Node Excision
1
Laparoscopy
1
Geriatric Assessment
1
Everolimus
1
Drug Therapy
1
Chemoradiotherapy
1
Capecitabine
1
ARRY-334543
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Gallbladder Neoplasms
×
durvalumab
×
Clear all
NCT06214572
2025-04-11
RUGB
Tata Memorial Centre
Phase 2/3
Recruiting
249 enrolled